May 8, 2018 / 10:57 AM / 15 days ago

BRIEF-Lynparza (Olaparib) Tablets Receive EU Approval For The Treatment Of Platinum-Sensitive Relapsed Ovarian Cancer

May 8 (Reuters) - Merck & Co Inc:

* LYNPARZA® (OLAPARIB) TABLETS RECEIVE EU APPROVAL FOR THE TREATMENT OF PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER

* MERCK & CO INC - NEW TABLET FORMULATION REDUCES DOSING TO TWO TABLETS TWICE DAILY

* MERCK - EMA APPROVED LYNPARZA TABLETS (300 MG TWICE DAILY) FOR USE AS A MAINTENANCE THERAPY WITH PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below